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The PLoS Medicine Debate
B
ackground to the debate: Several studies have found 
disparities in the outcome of medical procedures across 
different hospitals—better outcomes have been associated 
with higher procedure volume. An Institute of Medicine 
workshop found such a “volume–outcome relationship” for 
two types of cancer surgery: resection of the pancreas and 
esophagus (http://www.iom.edu/?id=31508). This debate 
examines whether physicians have an ethical obligation to 
inform patients of hospital outcome disparities for these 
cancers.
Nadine Housri and Leonidas Koniaris’ Viewpoint: 
Physicians Have an Ethical Duty to Inform 
Patients of Hospital Outcome Disparities for 
Select Cancers
Thirty years ago, Luft and colleagues published the 
mortality rates for 12 surgical procedures of varying 
complexity in 1,498 hospitals, finding the mortality of open-
heart surgery, vascular surgery, transurethral prostatectomy, 
and coronary bypass to be inversely related to hospital volume 
[1]. Since then, further studies have found an association 
between improved outcome and high hospital procedure 
volume [2–19] or teaching hospital status [20–23]. Such 
reports have led to calls for regionalization of care [12,24,25], 
and have served as the impetus leading consumer groups and 
policy makers to use hospital volume as a quality indicator 
and, in some cases, to direct patients to high-volume centers 
for select procedures [26,27] .
The results of outcomes studies, especially those for 
cancer, have generated significant interest among consumer 
groups and private organizations, some of which provide 
patients with hospital volume information on their Web sites 
[27]. In addition, a number of articles on volume–outcome 
studies have appeared in popular American newspapers 
and magazines [28–34]. These articles present a relatively 
simplistic view of volume–outcome data and may be subject to 
misinterpretation [35]. 
Since it is clear that patients are receiving information on 
hospital disparities in cancer treatment not only from their 
physicians but also from less informed sources, a crucial 
ethical question has arisen for the individual physician 
treating patients with cancer. Should primary care physicians, 
surgeons, and oncologists inform their patients of outcome 
disparities among hospitals? Should such information be 
disclosed as an element of informed consent? In response to 
one of the initial studies on volume–outcome relationships, 
Charles Culver and Bernard Gert argued in 1980 in favor of 
informing patients of volume–outcome disparities, where they 
exist [36]. However, almost 30 years later, it is questionable 
whether this information is disclosed during the informed 
consent process. Based on the principles of informed consent 
and the prevailing standards of disclosure, we argue that 
physicians have an ethical obligation to inform patients of 
hospital outcome disparities for select cancers.
The Scope of Informed Consent in Cancer Care
Informed consent, which aims to protect the autonomous 
choice of the patient, is traditionally defined in terms of 
two components: (1) the disclosure of information on a 
procedure, leading to the patient’s comprehension of this 
information; and (2) authorization by the patient to proceed 
with treatment [37]. Disclosure includes information on 
the nature of a procedure, potential risks and benefits, and 
alternative treatments. While patients are theoretically given 
adequate information to help them decide whether or not to be 
treated, they are given very little, if any, information to guide 
their decision on where to be treated. How often does the 
informed consent process include a discussion on the risks 
and benefits of treatment at a low-volume or nonteaching 
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hospital or the possibility of an alternative treatment at a 
high-volume or academic center? Withholding outcome 
data where substantial differences in short- and long-term 
outcomes are observed potentially costs patients the ability to 
make an informed decision on where they should seek care.
The Case for Informed Consent
Informed consent is often seen as a right of a patient and a 
duty or obligation of a physician [38]. Does a physician have 
an ethical obligation to share volume–outcome data when 
consenting a patient for treatment? And is it the patient’s 
right to know this information when making a decision?
The necessity of disclosure can be assessed through two 
prevailing standards—the “professional practice” standard 
and the “reasonable person” standard. According to the 
“professional practice” standard, adequate disclosure is 
determined by the professional community’s customary 
practices [37]. At the conclusion of the 2000 Institute of 
Medicine workshop examining evidence on the volume–
outcome relationship, the National Cancer Policy Board 
determined that the volume–outcome relationship was 
strongest and most consistent for resections of the pancreas 
and esophagus [39]. While the volume–outcome relationship 
is gaining strength for a number of other cancers involving 
complex surgeries [5,6,10,11,13,22], the only cancer 
resections for which the Agency for Healthcare Research and 
Quality lists hospital volume in their Inpatient Quality Indicators
are those of pancreatic and esophageal cancer. In addition, 
the Leapfrog coalition (http://www.leapfroggroup.org/), 
an alliance of large and small corporations that employs a 
total of over 20 million individuals, requires that employees 
who undergo one of five high-risk procedures must be cared 
for at high-volume centers. Two of the five procedures are 
pancreatic and esophageal cancer resections [40]. Therefore, 
we feel that the professional practice standard would, at 
the very least, support the disclosure of volume–outcome 
differences for patients undergoing pancreatic or esophageal 
cancer treatment.
Conversely, the “reasonable person” standard holds that 
the relevance of information is not based on the professional 
community’s practices, but rather on the significance that 
a reasonable person would attach to it in making a decision 
[37]. What value would a reasonable woman with metastatic 
breast cancer place on the information that treatment at 
a teaching hospital is associated with a significantly higher 
chance of five- and ten-year survival? [22]. Would knowing 
that a local low-volume hospital may provide a man with 
rectal cancer with a significantly higher risk of a postoperative 
colostomy or even death cause him to seek out care at a 
high-volume center? [23] According to Finlayson’s study 
on patient preferences for location of care, nearly half of 
surveyed patients stated that they would rather travel four 
hours to a distant center for a Whipple procedure than be 
treated at a local hospital if care at the distant center was 
associated with half the risk of operative mortality [41]. 
Interestingly, 45 out of 100 patients would not travel to a 
distant center if the risk was doubled at their local hospital, 
and almost one quarter of patients would rather face a 
six-times higher risk of operative mortality than travel for 
treatment. Thus while many patients may value outcome 
data in deciding where to have their surgeries, a similarly 
large number of patients will prefer local treatment, despite 
disparities in outcomes. The study makes no mention of 
the manner in which risks were framed when conveyed to 
the patient—“framing effects” during informed consent are 
known to influence patients’ decisions [37]. The value that a 
reasonable person would place on outcome data in selecting 
location of care remains uncertain. 
The reasonable person standard is one that can be very 
challenging for a physician to assess. In order to accurately 
evaluate what a reasonable person would find significant in 
making an informed decision, a physician must engage in 
discussion with the patient. Such discussion is also essential in 
allowing treatment to be a result of “shared decision-making” 
[38]. While informed consent and shared decision-making 
serve the same goal—to enhance a patient’s control over 
his or her own medical care—they are two distinct entities. 
Informed consent is a physician’s ethical and legal duty and 
mandates the two components outlined above: discussion 
of the procedure and explicit patient agreement or refusal. 
Shared decision-making, on the other hand, is a manner in 
which decisions may be made, involving an exchange of ideas 
between patient and doctor and collaboration on the decision 
itself [42]. We believe that for any cancer in which a volume–
outcome relationship has been defined, discussion of this 
relationship should be part of both processes. Additionally, 
disclosure of outcomes research should be a required 
component of informed consent for those cases in which the 
volume–outcome relationship is significant and consistent, 
and is supported by the professional practice standard of 
disclosure.
Consequences of Disclosure or Nondisclosure
Physicians may be hesitant in disclosing hospital outcome 
disparities for fear of migration of cancer patients from 
low-volume and nonteaching hospitals to high-volume and 
teaching hospitals. However, armed with knowledge of 
hospital-outcome data, patients will not necessarily choose 
to change hospitals—they may prefer to remain at a local 
hospital [31] or they may simply lack access to high-volume 
centers [43]. In addition, patients may not wish to travel 
to a high-volume center for cases in which treatment at a 
high-volume center confers only a small, albeit significant, 
advantage.
It is an ethical duty, and not fear of litigation, that should 
motivate physicians to provide full disclosure to their patients. 
Nevertheless, the legal implications of inadequate disclosure 
cannot be ignored. In the United States, the courts continue 
to differ in their definitions of adequate disclosure, and 
the states are split evenly between the two standards [44]. 
However, failures to inform patients of alternatives that may 
have otherwise yielded a better outcome have been met 
with legal action in recent years. In the case of Johnson v. 
Kokemoor, a neurosurgeon was successfully prosecuted for 
failure to accurately disclose risks of a basilar bifurcation 
aneurysm surgery performed by a surgeon at his level of 
experience. Furthermore, the Wisconsin Supreme Court 
decided that information on the availability of other centers 
and physicians better able to perform that procedure would 
have facilitated the plaintiff’s awareness of “all of the viable 
alternatives” and her ability to make an informed choice [45]. 
A similar conclusion was reached in the Australian case of 
Chappel v. Hart, which sided with a patient plaintiff for failure 
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experienced surgeon for a particular procedure [46]. “Loss 
of chance of a better outcome” is a recent development in 
Australian law in which negligence may be claimed without 
the need to prove causation. The loss of chance concept has 
been rejected by British courts. Nonetheless, more claims 
based on loss of chance are expected in Australia and may 
be successfully prosecuted unless rejected by the High Court 
[47].
A Question of Trust and Honesty
Full disclosure of outcomes research, whether it is during the 
mandated process of informed consent or the recommended 
shared decision-making part of care, is essential to maintain 
trust and honesty in the physician–patient relationship. More 
importantly, it will protect the cancer patient’s autonomy 
and sense of control, a value of paramount importance for a 
patient battling a potentially lethal disease.
Robert J. Weil’s Viewpoint: Such a Discussion 
Faces Logistic Hurdles and Risks Unintended 
Consequences
In their thoughtful and provocative viewpoint, Nadine 
Housri and Leonidas Koniaris propose that hospital outcome 
studies should be a necessary and obligatory component of 
the informed consent process ahead of offering surgery for 
cancer. Reviewing a number of the salient papers published 
over the past 30 years, they re-emphasize that, for some 
cancers, hospitals with higher volumes and/or teaching-
training facilities have statistically lower rates of postoperative 
mortality and increased rates of survival (both indicators 
of surgical quality). In the field of oncological surgery, this 
association is true only of resections for esophageal and 
pancreatic cancer.
Housri and Koniaris’ focus on both improving the 
delivery of health care and enhancing the shared decision-
making process with patients is commendable. However, 
one must also consider carefully the broader effects of 
adding yet another requirement (and potential barrier) 
to the patient–physician relationship. Housri and Koniaris 
argue that surgeons have an “ethical obligation to inform 
patients of hospital outcome disparities for select cancers,” 
but their proposal faces a number of logistic hurdles. And, 
to quote Robert Merton, their proposal could have several 
“unanticipated consequences.” (In his seminal 1936 paper, 
“The Unanticipated Consequences of Purposive Social 
Action,” Merton outlined various types of unintended 
outcomes that may follow an organized, positive, and rational 
action [48].)
Logistic Hurdles
There are a variety of hurdles to Housri and Koniaris’ 
proposal. For example, it is unclear who exactly should 
disclose the hospital outcomes data to the patient. Does the 
burden of disclosure fall upon the surgeon or the hospital? 
It is also unclear what exactly should be disclosed and which 
types of hospitals should be compared. For example, should 
local teaching or high-volume hospitals be compared with 
local community hospitals, across states, populations, nations, 
or all three? Given advances in devices, medicine, surgical 
approaches, and technology, is it possible to compare 
hospitals or even recent time periods, especially when faced 
with disease courses that may extend over years? Similarly, 
it remains unclear how to compare the rates of surgical 
complications or successful outcomes in patients of variable 
surgical risk. And there are major hurdles in understanding, 
computing, and then conveying to the patient the difficult 
concept that statistics apply to populations but not to an 
individual.
Unanticipated Consequences
One possible unintended consequence of mandating that 
physicians disclose hospital outcomes data is that hospitals 
or physicians may engage (overtly or subconsciously) in 
practices that help boost their hospital’s rating. For example, 
in an effort to maintain good outcomes data, will community 
hospitals refer high-risk patients to the teaching hospital? 
Similarly, will surgeons do less radical or less morbid 
operations that may have little effect on cancer outcome but 
improve complication rates substantially? And what might 
happen in the event that a hospital is found to have poor 
surgical outcomes compared to other hospitals, and yet no 
specific causative factor is identified by careful audit, and the 
surgeon’s personal outcomes are better than average? Should 
the surgeon switch hospitals? 
What is most worrisome, when considering unintended 
consequences, is that most patients do not fully grasp the 
strengths and limitations of outcomes measures [41]. Indeed, 
Finlayson and colleagues found that many patients wish, for 
a variety of reasons and in spite of their physician’s advice, 
to obtain care at a facility with a worse than average outcome 
[41].
Weaknesses in Outcomes Studies
A universal desire among physicians is to enhance and 
promote a patient’s welfare through improved outcomes. 
However, at present, outcomes studies remain incomplete 
for most cancers, frequently lag behind evolving standards 
of care for many tumors, and remain difficult to apply to the 
individual. For example, Koniaris and colleagues recently 
found that in the treatment of breast cancer, teaching 
hospitals were superior to community hospitals in terms of 
five-year mortality (p < 0.001) [22]. However, the disparity 
was only 3%–6% depending upon the type of community 
hospital, which may not represent a clinically meaningful 
difference, especially at the level of a single patient.
Furthermore, as Pfister and colleagues noted [49], teaching 
hospitals tend to enroll more patients on clinical trials. In 
most of these trials, enrollment criteria require extensive 
evaluation to exclude metastatic disease, which may use 
technology available only at specialized centers (for example, 
PET imaging). In many of these cases, if patients do not 
qualify for the clinical trial due to previously unsuspected 
advanced or metastatic disease, they return to their 
community hospital and may be reported from that hospital, 
at their original stage, to the registry. This leads to a potential 
selection bias in favor of teaching hospitals in registries with 
respect to “initial stage” and overall outcome [49].
Given the potential variety of unpredictable outcomes for 
a given patient, the time may not yet be ripe to insist upon 
incorporation of outcomes data into the informed consent 
process. Efforts should be focused on processes that assist and 
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and on more incisive studies that determine the individual 
and organizational actions that lead to positive outcomes, 
and that can be applied universally. The value of Housri and 
Koniaris’ viewpoint is that it should help stimulate our efforts 
to continuously seek improvements and refinements in the 
quality and performance of our care, so as to attain optimal 
results.
David Shalowitz’s Viewpoint: More Work Is 
Needed before Outcomes Data Are Routinely 
Used in Clinical Decision-Making
To what extent do volume–outcomes data matter in 
patients’ decision-making? The National Cancer Policy Board 
of the Institute of Medicine concluded that “volume per se 
does not result in good outcomes in health care but is instead 
a proxy measure for other factors [potentially including] 
physician skill, experienced interdisciplinary teams, or 
well-organized care processes” [39]. The volume–outcome 
relationship is therefore less likely to be valuable to patients 
selecting a cancer treatment site than the actual outcomes 
data from potential treating institutions. Put another way, 
outcomes data from multiple institutions are likely to be 
important to a patient’s selection of a treatment center, but 
the causes of differences in outcomes, whether case volume, 
teaching status, or otherwise, are far less likely to matter.
How, then, should outcomes data be communicated to 
patients? There are at least three possible strategies. The first 
is simply to ensure public access to hospital data, including 
outcomes data on different medical and surgical procedures, 
thus allowing the informed patient–consumer to select the 
best site for treatment. 
However, despite the current emphasis on patient-
centered medicine, we often prefer information critical to 
patient care to be communicated directly by a physician. 
A second strategy, therefore, would be for the physician 
to communicate outcomes data. When a patient has an 
established relationship with a primary care physician or 
specialist, outcomes data may be included in the process of 
determining what treatment course, if any, will be selected 
and where treatment will take place. For example, Housri and 
Koniaris note that while some patients may opt for treatment 
at the institution with the best outcomes, others may base 
their decision on proximity [41]. The shared decision-making 
interaction would likely best allow physicians to elicit patients’ 
relevant preferences. However, this strategy would require 
physicians to obtain and interpret up-to-date outcomes data, 
which may be difficult and time-consuming. 
A third option, as proposed by Housri and Koniaris, would 
be to incorporate outcomes data, where appropriate, into 
the consent form that the patient signs ahead of a surgical 
procedure—specifically in the “Risks” and “Alternatives 
to Treatment” sections of the form. On the one hand, 
surgeons may be best informed to discuss the relative risks 
and benefits of having a procedure performed at their 
institution versus another, and may be best placed to answer 
patients’ questions. On the other hand, consent for a surgical 
procedure is solicited after the treating institution has 
been selected, and patients may still have many questions. 
Revisiting the selection of treatment site may consequently 
take time away from other important aspects of the consent 
process. Furthermore, including outcomes data at this point 
would make surgeons responsible for interpreting other 
institutions’ outcomes data as well as their own, which may be 
neither possible nor prudent. Despite their best intentions, 
treating surgeons and institutions would be placed in the 
somewhat awkward position of determining whether to 
recommend a patient to another—perhaps competing—
institution. This conflict of interest must be avoided whenever 
possible.
Housri and Koniaris’ arguments do support a responsibility 
on the part of surgeons and hospitals to track their own 
complication rates and disclose these data accurately and 
understandably in the consent process for procedures. 
Competent adult patients may then decide whether 
the benefits and risks are compatible with pursuing the 
procedure. However, the ethical responsibility of hospitals 
to discuss other institutions’ outcomes is still indeterminate. 
Selection of treatment site is, at this point, best done as part 
of a dynamic decision-making process in which all aspects 
of treatment can be evaluated in the context of the patient’s 
preferences, including the importance of local treatment, 
differences in outcomes, existing relationships with surgeons, 
and other intangible considerations.
Importantly, Housri and Koniaris have also drawn attention 
to the content of the “Alternatives to Treatment” section of 
informed consent documents. This section has traditionally 
focused on alternative approaches to treatment rather than 
alternative treating physicians or institutions. However, 
careful examination of relevant ethical principles and legal 
precedents may prompt reconsideration of this standard. 
The role of outcomes data may be important to patients’ 
treatment decision-making, but more work must be done to 
clarify: (1) patients’ desire for outcomes data; (2) the proper 
arena(s) for communicating such data; and (3) the ethical/
legal underpinnings of using outcomes data in treatment 
decision-making. Only then can discussion of outcomes data 
be mandated in selection of an institution for surgical care.  
References
1. Luft HS, Bunker JP, Enthoven AC (1979) Should operations be 
regionalized? The empirical relation between surgical volume and mortality. 
N Engl J Med 301: 1364-1369.
2. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, et al. (2001) The 
influence of hospital volume on survival after resection for lung cancer. N 
Engl J Med 345: 181-188.
3. Begg CB, Cramer LD, Hoskins WJ, Brennan MF (1998) Impact of hospital 
volume on operative mortality for major cancer surgery. JAMA 280: 
1747-1751.
4. Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, 
et al. (1999) Effect of hospital volume on in-hospital mortality with 
pancreaticoduodenectomy. Surgery 125: 250-256.
5. Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, et al. (2002) 
Hospital volume and surgical mortality in the United States. N Engl J Med 
346: 1128-1137.
6. Birkmeyer JD, Sun Y, Wong SL, Stukel TA (2007) Hospital volume and late 
survival after cancer surgery. Ann Surg 245: 777-783.
7. Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN 
(1999) Relationship between hospital volume and late survival after 
pancreaticoduodenectomy. Surgery 126: 178-183.
8. Ellison LM, Heaney JA, Birkmeyer JD (2000) The effect of hospital volume 
on mortality and resource use after radical prostatectomy. J Urol 163: 
867-869.
9. Finlayson EV, Birkmeyer JD (2003) Effects of hospital volume on life 
expectancy after selected cancer operations in older adults: A decision 
analysis. J Am Coll Surg 196: 410-417.
10. Finlayson EV, Goodney PP, Birkmeyer JD (2003) Hospital volume and 
operative mortality in cancer surgery: A national study. Arch Surg 138: 
721-725; discussion 726.
11. Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF (2005) Long-term 
survival is superior after resection for cancer in high-volume centers. Ann 
Surg 242: 540-544; discussion 544-547.PLoS Medicine  |  www.plosmedicine.org 1417 October 2008  |  Volume 5  |  Issue 10  |  e214
12. Glasgow RE, Mulvihill SJ (1996) Hospital volume influences outcome 
in patients undergoing pancreatic resection for cancer. West J Med 165: 
294-300.
13. Guller U, Safford S, Pietrobon R, Heberer M, Oertli D, et al. (2005) High 
hospital volume is associated with better outcomes for breast cancer surgery: 
Analysis of 233,247 patients. World J Surg 29: 994-999; discussion 999-1000.
14. Gutierrez JC, Perez EA, Moffat FL, Livingstone AS, Franceschi D, et al. 
(2007) Should soft tissue sarcomas be treated at high-volume centers? An 
analysis of 4205 patients. Ann Surg 245: 952-958.
15. Hollenbeck BK, Daignault S, Dunn RL, Gilbert S, Weizer AZ, et al. (2007) 
Getting under the hood of the volume-outcome relationship for radical 
cystectomy. J Urol 177: 2095-2099; discussion 2099.
16. Hollenbeck BK, Wei Y, Birkmeyer JD (2007) Volume, process of care, and 
operative mortality for cystectomy for bladder cancer. Urology 69: 871-875.
17. Roohan PJ, Bickell NA, Baptiste MS, Therriault GD, Ferrara EP, et al. 
(1998) Hospital volume differences and five-year survival from breast 
cancer. Am J Public Health 88: 454-457.
18. Schrag D, Cramer LD, Bach PB, Cohen AM, Warren JL, et al. (2000) 
Influence of hospital procedure volume on outcomes following surgery for 
colon cancer. JAMA 284: 3028-3035.
19. Schrag D, Panageas KS, Riedel E, Cramer LD, Guillem JG, et al. (2002) 
Hospital and surgeon procedure volume as predictors of outcome following 
rectal cancer resection. Ann Surg 236: 583-592.
20. Cheung M, Hamilton K, Sherman R, Byrne MM, Nguyen DM, et al. (2008) 
Impact of teaching facility status and high volume centers on outcomes for 
lung cancer resection: An examination of 13,469 surgical patients. Ann Surg 
Oncol. E-pub 4 July 2008.
21. Dimick JB, Cowan JA Jr., Colletti LM, Upchurch GR Jr. (2004) Hospital 
teaching status and outcomes of complex surgical procedures in the United 
States. Arch Surg 139: 137-141.
22. Gutierrez JC, Hurley JD, Housri N, Perez EA, Koniaris LG (2008) Are many 
community hospitals under-treating breast cancer? Lessons from 24,834 
patients. Ann Surg 248: 154-162.
23. Gutierrez JC, Kassira N, Salloum RM, Franceschi D, Koniaris LG (2007) 
Surgery for rectal cancer performed at teaching hospitals improves survival 
and preserves continence. J Gastrointest Surg 11: 1441-1448; discussion 
1448-1450.
24. Gordon TA, Bowman HM, Tielsch JM, Bass EB, Burleyson GP, et al. (1998) 
Statewide regionalization of pancreaticoduodenectomy and its effect on in-
hospital mortality. Ann Surg 228: 71-78.
25. Gordon TA, Burleyson GP, Tielsch JM, Cameron JL (1995) The effects 
of regionalization on cost and outcome for one general high-risk surgical 
procedure. Ann Surg 221: 43-49.
26. Birkmeyer JD, Lucas FL, Wennberg DE (1999) Potential benefits of 
regionalizing major surgery in Medicare patients. Eff Clin Pract 2: 277-283.
27. Birkmeyer JD, Skinner JS, Wennberg DE (2002) Will volume-based referral 
strategies reduce costs or just save lives? Health Aff (Millwood) 21: 234-241.
28. Grady D (2007 July 29) Push hard for the answers you require. The 
New York Times. Available: http://www.nytimes.com/2007/07/29/
health/29WHATSIDE.html. Accessed 17 September 2008.
29. Gupta S (2003 December 8) Practice, practice. Time Magazine. Available: 
http://www.time.com/time/magazine/article/0,9171,1006401,00.html.
Accessed 17 September 2008.
30. Hatch C (2005 July 18) Beyond safety: Really sick patients need expertise—
Not just protection. US News & World Report. Available: http://health.
usnews.com/usnews/health/articles/050718/18safe.htm. Accessed 17 
September 2008.
31. Kolata G (2006 July 2) Looking for answers when choosing care. The New 
York Times. Available: http://www.nytimes.com/2006/06/30/nyregion/
nyregionspecial2/02Rhosp.html. Accessed 17 September 2008.
32. Perry P (2002 May 1) Pancreatic cancer: The Whipple. For patients 
undergoing a pancreaticoduodenectomy—A complex, high-risk operation 
for pancreatic cancer also known as the Whipple procedure—Choosing a 
high-volume hospital with an experienced surgeon yields the best outcome. 
The Saturday Evening Post.
33. Szabo L (2005 July 25) Study finds better survival rates at ‘high-volume’ 
hospitals. USA Today. Available: http://www.redorbit.com/news/
health/184929/study_finds_better_survival_rates_at_highvolume_
hospitals/. Accessed 17 September 2008.
34. Villarosa L (2002 April 11) Studies tie success of some operations to 
number a hospital does. The New York Times. Available: http://query.
nytimes.com/gst/fullpage.html?res=9E05E3DB1F3DF932A25757C0A9649C
8B63. Accessed 17 September 2008.
35. Asp K (2004) Go with a high-volume doc. Prevention: Rodale. Available: 
http://www2.prevention.com/cda/article/go-with-a-high-volume-doc/17
56323b0b803110VgnVCM20000012281eac____/health/healthy.lifestyle/
smart.medical.decisions/. Accessed 17 September 2008.
36. Culver CM, Gert B (1980) Regionalization of surgical services. N Engl J Med 
302: 1034-1035.
37. Beauchamp TL, Childress JF (2001) Principles of biomedical ethics. New 
York: Oxford University Press.
38. Berg JW, Appelbaum PS, Lidz CW, Parker LS (2001) Informed consent. 
New York: Oxford University Press.
39. Hewitt M, Petitti D (2001) Interpreting the volume-outcome relationship 
in the context of cancer care. National Cancer Policy Board, Institute of 
Medicine. Available: http://www.nap.edu/catalog.php?record_id=10160. 
Accessed 17 September 2008.
40. Dimick JB, Birkmeyer JD, Upchurch GR Jr. (2005) Measuring surgical 
quality: What’s the role of provider volume? World J Surg 29: 1217-1221.
41. Finlayson SR, Birkmeyer JD, Tosteson AN, Nease RF Jr. (1999) Patient 
preferences for location of care: Implications for regionalization. Med Care 
37: 204-209.
42. Whitney SN, McGuire AL, McCullough LB (2004) A typology of shared 
decision making, informed consent, and simple consent. Ann Intern Med 
140: 54-59.
43. Dimick JB, Finlayson SR, Birkmeyer JD (2004) Regional availability of 
high-volume hospitals for major surgery. Health Aff (Millwood) Suppl Web 
Exclusives: VAR45- VAR 53.
44. King JS, Moulton B (2006) Rethinking informed consent: The case for 
shared medical decision-making. Am J Law Med 32: 429-501.
45. Wisconsin Supreme Court (1996) Johnson v .Kokemoor. 199 Wis.2d 615. 
545 N.E. 2d 495.
46. High Court of Australia (1998) Chappel v. Hart. 156 ALR 517.
47. Tibballs J (2007) Loss of chance: A new development in medical negligence 
law. Med J Aust 187: 233-235.
48. Merton RK (1936) The unanticipated consequences of purposive social 
action. Am Sociol Rev 1: 894-904.
49. Pfister DG, Wells CK, Chan CK, Feinstein AR (1990) Classifying clinical 
severity to help solve problems of stage migration in nonconcurrent 
comparisons of lung cancer therapy. Cancer Res 50: 4664-4669.